Latest Anagenics (Asx:An1) News

Anagenics Limited has announced a two-tranche placement to raise A$2.25 million, aiming to expand its health and wellness brands while retiring debt and supporting working capital.

Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Anagenics Limited reports improved operating cash flow and strong sales from its Bouf Haircare brand, while exploring international expansion and a key licensing deal.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Anagenics Ltd has reported a significant earnings turnaround in 3Q25 following a strategic business restructure, alongside securing a multi-year royalty agreement worth $4.4 million with York Street Brands.

Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.

Anagenics Limited has reported a net profit before tax of $138,000 for the quarter ended March 31, 2025, marking a significant turnaround following recent restructuring efforts. Despite a temporary revenue setback due to a warehousing transition, the company’s operating cash flow improved markedly.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

Anagenics reports a marked reduction in operating cash outflow and expenses following a strategic restructuring, setting the stage for improved financial stability in the coming quarter.